Analysis Medicamen Biotech Limited (MEDICAMEQ)
5/25/2024
Analysis of Medicamen Biotech Limited (MEDICAMEQ)
Medicamen Biotech Limited has shown some fluctuations in its stock price over the past few days. The RSI indicator has been hovering around the mid-range, indicating a balanced market sentiment. The MACD indicator has shown some variability, with the signal line crossing the MACD line on some days.The moving averages (SMA, EMA, WMA) have been relatively close to each other, suggesting a stable trend in the stock price. However, the stock has experienced some price volatility, with the price reaching both highs and lows during the analyzed period.
Overall, the stock of Medicamen Biotech Limited seems to be trading in a range-bound pattern with some short-term fluctuations. Traders and investors may need to closely monitor the price movements and indicators for potential trading opportunities.
Income statement 💸
These are the revenues. Draw conclusions.Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets fluctuate, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have been increasing steadily, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Shareholders' equity has been fluctuating, with the highest value in 2018 at $107,147,000,000.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The results for January 31, 2025, were released after hours. The results for October 31, 2024, were not provided at the time. The results for August 1, 2024, showed an earnings per share (EPS) estimate of 1.33.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits for a specific company.In terms of financials, the company has a strong operating cash flow and levered free cash flow. The balance sheet shows a healthy current ratio, but a high total debt to equity ratio. The profit margin and operating margin are both positive, indicating profitability. The company's fiscal year ends in September 2023, with notable figures such as EBITDA, revenue, and net income.
Moving on to stock statistics, we see details such as short ratio, float shares, shares outstanding, and percentages held by insiders and institutions. The valuation metrics provide insights into the company's price-to-earnings ratios, enterprise value, and market capitalization.
The stock price summary includes information on beta, moving averages, and the range of the stock price over the past year. Lastly, the dividends and splits section outlines dividend-related details such as payout ratio, dividend dates, dividend yields, and historical split information.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show a pattern of common stock repurchase and issuance, as well as long-term debt issuance and payments.
6. Investing activities include significant amounts related to the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company seems to be managing its cash flow effectively, with a focus on operational efficiency and strategic investments.
Earnings estimate
Based on analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average EPS estimate is $1.33, with a low estimate of $1.27 and a high estimate of $1.36. This shows growth compared to the EPS of $1.26 from a year ago.
2. For the next quarter ending on September 30, 2024, the average EPS estimate is $1.53, with a low estimate of $1.44 and a high estimate of $1.63. This also indicates growth compared to the EPS of $1.46 from a year ago.
3. For the current year ending on September 30, 2024, the average EPS estimate is $6.59, with a low estimate of $6.43 and a high estimate of $6.92. This reflects an increase from the EPS of $6.13 from the previous year.
4. Looking ahead to the next year ending on September 30, 2025, the average EPS estimate is $7.23, with a low estimate of $6.40 and a high estimate of $7.90. This forecast suggests further growth compared to the EPS of $6.59 from the previous year.
Overall, the analysts' estimates point towards a positive outlook for the company's earnings per share, with expected growth in both the short term and the long term.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.
These estimates suggest a moderate growth trend in both quarterly and annual sales for the company, with slightly higher growth rates expected in the upcoming fiscal year.
Growth estimates
Based on the consensus estimates provided, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.6%.
2. Next Quarter: The estimated growth rate for the next quarter is 4.8%.
3. Current Year: The estimated growth rate for the current year is 7.5%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average growth rate for the past 5 years is 20.1% per annum.
6. Next 5 Years (per annum): The estimated growth rate for the next 5 years is 11% per annum.
These estimates suggest a positive growth trend for the company, with a slightly lower growth rate expected in the near term compared to the historical average. However, the company is still projected to experience solid growth both in the short term and over the next 5 years according to analyst consensus.
Price target
Based on the analysts' forecast, the future price of the security is expected to range between $164 (low) and $250 (high), with a median estimate of $200 and an average estimate of $202.26. The current price of the security is $191.57. It appears that the analysts are generally optimistic about the future price of the security, with the average and median estimates both higher than the current price.MACD of MEDICAMEQ
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
